Publication Date
12-1-2017
Journal
The Texas Heart Journal
DOI
10.14503/THIJ-16-5955
PMID
29276436
Publication Date(s)
December 2017
Language
English
PMCID
PMC5737148
PubMedCentral® Posted Date
12-17-2017
PubMedCentral® Full Text Version
Post-Print
Published Open-Access
yes
Keywords
Biomarkers/blood, cardiomyopathy, hypertrophic/genetics, cardiovascular physiologic phenomena/genetics, gene expression regulation, hypertrophy, left ventricular/diagnosis, microRNAs/blood/isolation & purification/physiology, real-time polymerase chain reaction, ROC curve, sensitivity and specificity
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Abstract
MicroRNA-27b (miR-27b) is frequently upregulated in pressure-overloaded hypertrophic hearts. The clinical implications of aberrant circulating miR-27b in the diagnosis and management of left ventricular hypertrophy warrant study. We investigated whether serum miR-27b is a biomarker for left ventricular hypertrophy (LVH).
We used stem-loop reverse-transcription quantitative polymerase chain reaction techniques to analyze serum miR-27b levels in 200 hypertensive patients with LVH, 100 hypertensive patients without LVH, and 100 healthy volunteers. We found that serum miR-27b levels were significantly higher in the hypertensive patients with LVH than in the hypertensive patients without LVH and in the healthy volunteers. Upon receiver operating characteristic curve analysis, serum miR-27b had an area under the curve of 0.885 with 91% sensitivity and 73% specificity in distinguishing hypertensive patients with LVH from healthy volunteers (P=0.021), and an area under the curve of 0.818 with 79.1% sensitivity and 70.3% specificity in distinguishing hypertensive patients with LVH from those without LVH (P=0.036). We conclude that circulating miR-27b might serve as a specific, noninvasive biomarker in screening for LVH.